Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.04 -1.0%	$1.27	$0.86 ▼ $3.78	$227.48M	0.35	5.10 million shs	3.66 million shs
DRUG Bright Minds Biosciences	$38.82 +11.6%	$28.86	$0.94 ▼ $79.02	$273.45M	-6.07	47,315 shs	164,381 shs
GALT Galectin Therapeutics	$4.15 +8.1%	$2.50	$0.73 ▼ $4.41	$262.66M	0.82	331,198 shs	814,354 shs
INMB INmune Bio	$2.56 -8.2%	$4.39	$1.89 ▼ $11.64	$68.06M	0.97	3.18 million shs	1.31 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.70%	-17.46%	-10.34%	-57.89%
DRUG Bright Minds Biosciences	0.00%	+15.43%	+49.71%	+21.16%	+3,494.44%
GALT Galectin Therapeutics	0.00%	+13.70%	+69.39%	+200.72%	+97.62%
INMB INmune Bio	0.00%	0.00%	+14.80%	-63.22%	-63.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.9835 of 5 stars	4.4	2.0	1.1	2.5	0.6
DRUG Bright Minds Biosciences	2.4004 of 5 stars	3.6	2.0	2.7	2.5	0.0
GALT Galectin Therapeutics	2.3783 of 5 stars	3.5	1.0	3.0	3.3	0.0
INMB INmune Bio	2.5847 of 5 stars	3.3	4.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	711.97% Upside
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	114.45% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	44.58% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	618.75% Upside

Current Analyst Ratings Breakdown

Latest INMB, DRUG, ALLO, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	11,373.96	N/A	N/A	$2.01 per share	0.52
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
INMB INmune Bio	$10K	6,804.48	N/A	N/A	$1.45 per share	1.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/13/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/12/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-116.46%	-89.89%	N/A

Latest INMB, DRUG, ALLO, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q3 2025	DRUG Bright Minds Biosciences	-$0.59	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
DRUG Bright Minds Biosciences	N/A	126.01	126.01
GALT Galectin Therapeutics	N/A	0.08	0.08
INMB INmune Bio	N/A	2.64	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
DRUG Bright Minds Biosciences	40.52%
GALT Galectin Therapeutics	11.68%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
DRUG Bright Minds Biosciences	42.66%
GALT Galectin Therapeutics	50.10%
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
INMB INmune Bio	10	26.58 million	17.09 million	Optionable

INMB, DRUG, ALLO, and GALT Headlines

Recent News About These Companies

BTIG Reaffirms Their Hold Rating on Inmune Bio (INMB)

August 10 at 12:20 PM | theglobeandmail.com

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?

August 10 at 12:20 PM | finance.yahoo.com

Inmune Bio (INMB) was downgraded to a Sell Rating at Scotiabank

August 9 at 4:17 PM | theglobeandmail.com

Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s

August 9 at 4:17 PM | theglobeandmail.com

INmune Bio (INMB) Q2 Loss Widens 110%

August 8 at 8:44 PM | aol.comA

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

August 8 at 4:06 PM | seekingalpha.com

INmune Bio (NASDAQ:INMB) Downgraded by Wall Street Zen to Sell

August 5, 2025 | americanbankingnews.com

INmune Bio stock soars after prostate cancer trial meets endpoints

August 4, 2025 | investing.com

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | finance.yahoo.com

INmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals

August 4, 2025 | msn.com

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | globenewswire.com

INmune Bio (NASDAQ:INMB) Cut to Sell at Wall Street Zen

August 3, 2025 | marketbeat.com

INmune Bio options imply 14.9% move in share price post-earnings

August 1, 2025 | msn.com

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025 | globenewswire.com

INmune Bio (INMB) to Release Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

2BNS, INMB : INmune Bio Rebounds Sharply During After Hours Trading: What&...

July 28, 2025 | benzinga.com

INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Moderate Buy" by Brokerages

July 26, 2025 | marketbeat.com

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

July 25, 2025 | manilatimes.netM

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

July 4, 2025 | seekingalpha.com

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

July 4, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
By Jordan Chussler | August 9, 2025
View Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
By Leo Miller | July 27, 2025
View PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
By Leo Miller | August 8, 2025
View Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

INMB, DRUG, ALLO, and GALT Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.04 -0.01 (-0.95%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.04 +0.00 (+0.48%)

As of 08/8/2025 07:19 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Bright Minds Biosciences NASDAQ:DRUG

$38.82 +4.02 (+11.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$39.35 +0.53 (+1.37%)

As of 08/8/2025 05:23 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Galectin Therapeutics NASDAQ:GALT

$4.15 +0.31 (+8.07%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.28 +0.14 (+3.25%)

As of 08/8/2025 07:59 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

INmune Bio NASDAQ:INMB

$2.56 -0.23 (-8.24%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.52 -0.04 (-1.56%)

As of 08/8/2025 07:59 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time